Carregant...

Adoption of Sacubitril/Valsartan for the Management of Patients with Heart Failure

BACKGROUND: The United States Food and Drug Administration (FDA) approved the use of sacubitril/valsartan in patients with heart failure (HF) and reduced ejection fraction (HFrEF) in July 2015We aimed to assess the adoption and prescription drug costs of sacubitril/valsartan in its first 18 months f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Circ Heart Fail
Autors principals: Sangaralingham, Lindsey R., Sangaralingham, S. Jeson, Shah, Nilay D., Yao, Xiaoxi, Dunlay, Shannon M.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5820776/
https://ncbi.nlm.nih.gov/pubmed/29453287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004302
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!